Proteomics, in recent past, has witnessed tremendous growth in its ability to generate, refine and apply a large amount of qualitative and quantitative data for solving biological problems. But our progress is challenged by the other dimensions of biological complexity. Simple proteomics from mere identification and relative quantitation is now shifting gear to handle the diversity offered by Post-translational modifications (PTMs). Biological outcome of the same genetic framework is sometimes holistically different from each other owing to differential protein behavior via modulation of the chemical envelope on protein, protein-protein interactions (PPI), enzymatic activity, protein stability, etc. in animal, plant, and human. There are more than three hundred PTM modifications known for eukaryotic cells. The identification of PTMs offers challenges not only in terms of the need for more sophisticated instrumentation but also from viewpoint of interpretation of big data which is more dynamic, flexible and unique to the individual. Understanding PTMs therefore is the future of proteomics which requires more trained manpower specialized in big data analyses. The dream of individualized prescription probably revolves around this big leap in our understanding of how PTMs work and our ability to stitch the layers of information which connects all omics.
The PSI conference (ICPBHF-2019) has created an opportunity to bring all interested stakeholders including clinicians, researchers, and bioinformatics experts on one platform to deliberate in-depth to carve the way for future. This will offer a beginning of national and international collaboration among research groups active in the field of animal, plant and human health around the world.